AMENDMENTS TO THE CLAIMS

1-81. (Canceled)

82. (Currently Amended) A compound ~~according to claim 72 having~~ of the formula (VII):



(VII)

or a salt[[,]] or N-oxide ~~or solvate~~ thereof;

~~wherein R^{1d} is a group R^{1a} as defined in claim 72.~~

wherein A is $-(CH_2)_m-(B)_n-$; where m is 0 or 1, n is 1 and B is C=O or $NR^g(C=O)$; and R^g is hydrogen; and

R^{1d} is a group R^1 where R^1 is hydrogen, an optionally substituted carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C_{1-8} hydrocarbyl group,

wherein the optional substituents for the C_{1-8} hydrocarbyl group are selected from hydroxy, oxo, alkoxy, carboxy, halogen, cyano, nitro, amino, mono- or di-C_{1-4} hydrocarbylamino, and monocyclic or bicyclic carbocyclic and heterocyclic groups having from 3 to 12 ring members;

and, wherein the carbocyclic and heterocyclic groups in each instance are unsubstituted or substituted by one or more substituent groups R^{10} selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^c, SO_2NR^c or NR^cSO_2; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen,

cyano, nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$; or two adjacent groups R^{10}, together with the carbon atoms or heteroatoms to which they are attached may form a 5-membered heteroaryl ring or a 5- or 6-membered non-aromatic carbocyclic or heterocyclic ring, wherein the said heteroaryl and heterocyclic groups contain up to 3 heteroatom ring members selected from N, O and S;

R^c is selected from hydrogen and C_{1-4} hydrocarbyl; and

X^1 is O, S or NR^c and X^2 is =O, =S or $=NR^c$;

and provided that where the substituent group R^{10} comprises or includes a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group may be unsubstituted or may itself be substituted with one or more further substituent groups R^{10} and wherein (a) such further substituent groups R^{10} include carbocyclic or heterocyclic groups, which are not themselves further substituted; or (b) the said further substituents do not include carbocyclic or heterocyclic groups but are otherwise selected from the groups listed above in the definition of R^{10}.

83. (Currently Amended) A compound according to claim 82, or a salt or N-oxide thereof, having the formula (VIIa):



(VIIa).

84-85. (Canceled)

86. (Withdrawn/Currently Amended) A method for treating a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering

to the mammal in an amount effective in inhibiting abnormal cell growth a compound according to claim 82, or a salt or N-oxide thereof. ~~of formula (I):~~



~~(I)~~

~~or a salt, N-oxide or solvate thereof;~~

~~wherein~~

~~X is CR^5 or N;~~

~~A is a bond or $-(CH_2)_m-(B)_n-$;~~

~~B is C=O, NR^g(C=O) or O(C=O) wherein R^g is hydrogen or C_{1-4} hydrocarbyl optionally substituted by hydroxy or C_{1-4} alkoxy;~~

~~m is 0, 1 or 2;~~

~~n is 0 or 1;~~

~~R^0 is hydrogen or, together with NR^g when present, forms a group $-(CH_2)_p-$ wherein p is 2 to 4;~~

~~R^1 is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C_{1-8} hydrocarbyl group;~~

~~R^2 is hydrogen, halogen, methoxy, or a C_{1-4} hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy;~~

~~R^3 and R^4 together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; and~~

~~R^5 is hydrogen, a group R^2 or a group R^{10} wherein R^{10} is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^e, SO_2NR^e or NR^eSO_2; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and~~

~~heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NR^e, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;~~

~~R^e is selected from hydrogen and C_{1-4} hydrocarbyl; and~~

~~X^1 is O, S or NR^e and X^2 is =O, =S or =NR^e.~~

87-95. (Canceled)

96. (Currently Amended) A pharmaceutical composition comprising a compound as defined in claim [[72]] 82, or a salt or N-oxide thereof, and a pharmaceutically acceptable carrier.

97. (Withdrawn) A process for the preparation of a compound as defined in claim 72, which process comprises:

reacting a compound of the formula:



with a compound of the formula R^{1a}-A' wherein A' is an isocyanate group N=C=O, or a group CO_2H or an activated derivative thereof;

and optionally thereafter converting one compound of the formula (IV) into another compound of the formula (IV).

98. (Withdrawn) A process for the preparation of a compound as defined in claim 72, which process comprises:

reacting a compound of the formula:



with a diamine compound of the formula:



wherein R^{1a}, A, R^3 and R^4 are as defined in claim 72; and optionally thereafter converting one compound of the formula (IV) into another compound of the formula (IV).

99. (Canceled)

100. (New) A compound according to claim 82, or a salt or N-oxide thereof, wherein R^1 is an optionally substituted monocyclic or bicyclic carbocyclic or heterocyclic group having from 3 to 12 ring members.

101. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is an optionally substituted monocyclic or bicyclic carbocyclic or heterocyclic group having from 3 to 10 ring members.

102. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is unsubstituted.

103. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is substituted by 1 or 2 or 3 or 4 substituents R^{10}.

104. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is a substituted group and the substituents on R^1 are selected from the group R^{10a} consisting of halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, heterocyclic groups having 5 or 6 ring members and up to 2 heteroatoms selected from O, N and S, a group R^a-R^b wherein R^a is a bond, O, CO, $X^3C(X^4)$, $C(X^4)X^3$, $X^3C(X^4)X^3$, S, SO, or SO_2, and R^b is selected from hydrogen, a heterocyclic group having 5 or 6 ring members and up to 2 heteroatoms selected from O, N and S, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano,

nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having 5 or 6 ring members and up to 2 heteroatoms selected from O, N and S; wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, $X^3C(X^4)$, $C(X^4)X^3$ or $X^3C(X^4)X^3$; X^3 is O or S; and X^4 is =O or =S.

105. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is a substituted group and the substituents on R^1 are selected from the group R^{10b} consisting of halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, a group R^a-R^b wherein R^a is a bond, O, CO, $X^3C(X^4)$, $C(X^4)X^3$, $X^3C(X^4)X^3$, S, SO, or SO_2, and R^b is selected from hydrogen and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy; wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, $X^3C(X^4)$, $C(X^4)X^3$ or $X^3C(X^4)X^3$; X^3 is O or S; and X^4 is =O or =S.

106. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein the substituents on R^1 are selected from halogen, hydroxy, trifluoromethyl, a group R^a-R^b wherein R^a is a bond or O, and R^b is selected from hydrogen and a C_{1-4} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxyl and halogen.

107. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is a phenyl group which is 2,6-disubstituted, 2,3-disubstituted, 2,4-disubstituted 2,5-disubstituted, 2,3,6-trisubstituted or 2,4,6-trisubstituted.

108. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is a phenyl group which is disubstituted at positions 2- and 6- with substituents selected from fluorine, chlorine and R^a-R^b, where R^a is O and R^b is C_{1-4} alkyl.

109. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein R^1 is a substituted or unsubstituted non-aromatic carbocyclic group having from 3 to 7 ring members.

110. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein the substituted or unsubstituted non-aromatic carbocyclic group has from 3 to 6 ring members.

111. (New) A compound according to claim 100, or a salt or N-oxide thereof, wherein the substituted or unsubstituted non-aromatic carbocyclic group R^1 is a cycloalkyl group.

112. (New) A compound according to claim 82, or a salt or N-oxide thereof, wherein A is NH(C=O) or C=O and R^{1d} is a group R^{1a}

wherein R^{1a} is selected from:

- a 6-membered monocyclic aryl group substituted by one to three substituents R^{10c} provided that when the aryl group is substituted by a methyl group, at least one substituent other than methyl is present;
- a 6-membered monocyclic heteroaryl group containing a single heteroatom ring member which is nitrogen, the heteroaryl group being substituted by one to three substituents R^{10c};
- a 5-membered monocyclic heteroaryl group containing up to three heteroatom ring members selected from nitrogen and sulphur, and being optionally substituted by one to three substituents R^{10c};
- a 5-membered monocyclic heteroaryl group containing a single oxygen heteroatom ring member and optionally a nitrogen heteroatom ring member, and being substituted by one to three substituents R^{10c} provided that when the heteroaryl group contains a nitrogen ring member and is substituted by a methyl group, at least one substituent other than methyl is present;
- bicyclic aryl and heteroaryl groups having up to four heteroatom ring members and wherein either one ring is aromatic and the other ring is non-aromatic, or wherein both rings are aromatic, the bicyclic groups being optionally substituted by one to three substituents R^{10c};
- four-membered, six-membered and seven-membered monocyclic C-linked saturated heterocyclic groups containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, the heterocyclic groups being optionally substituted by one to

three substituents R^{10c} provided that when the heterocyclic group has six ring members and contains only one heteroatom which is oxygen, at least one substituent R^{10c} is present;

- a five membered monocyclic C-linked saturated heterocyclic group containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, the heterocyclic group being optionally substituted by one to three substituents R^{10c} provided that when the heterocyclic group has five ring members and contains only one heteroatom which is nitrogen, at least one substituent R^{10c} other than hydroxy is present;
- four and six membered cycloalkyl groups optionally substituted by one to three substituents R^{10c};
- three and five membered cycloalkyl groups substituted by one to three substituents R^{10c}; and
- a group Ph'$CR^{17}R^{18}$- where Ph' is a phenyl group substituted by one to three substituents R^{10c}; R^{17} and R^{18} are the same or different and each is selected from hydrogen and methyl; or R^{17} and R^{18} together with the carbon atom to which they are attached form a cyclopropyl group; or one of R^{17} and R^{18} is hydrogen and the other is selected from amino, methylamino, C_{1-4} acylamino, and C_{1-4} alkoxycarbonylamino;
- unsubstituted phenyl and phenyl substituted with one or more methyl groups;
- an unsubstituted 6-membered monocyclic heteroaryl group containing a single heteroatom ring member which is nitrogen;
- unsubstituted furyl;
- a 5-membered monocyclic heteroaryl group containing a single oxygen heteroatom ring member and a nitrogen heteroatom ring member, and being unsubstituted or substituted by one or more methyl groups;
- an unsubstituted six membered monocyclic C-linked saturated heterocyclic group containing only one heteroatom which is oxygen; and
- unsubstituted three and five membered cycloalkyl groups;

and R^{10c} is selected from:

- halogen;

- hydroxyl;
- C_{1-4} hydrocarbyloxy optionally substituted by one or more substituents selected from hydroxyl and halogen;
- C_{1-4} hydrocarbyl substituted by one or more substituents selected from hydroxyl, halogen and five and six-membered saturated heterocyclic rings containing one or two heteroatom ring members selected from nitrogen, oxygen and sulphur;
- S-C_{1-4} hydrocarbyl;
- phenyl optionally substituted with one to three substituents selected from C_{1-4} alkyl, trifluoromethyl, fluoro and chloro;
- heteroaryl groups having 5 or 6 ring members and containing up to 3 heteroatoms selected from N, O and S, the heteroaryl groups being optionally substituted with one to three substituents selected from C_{1-4} alkyl, trifluoromethyl, fluoro and chloro;
- 5- and 6-membered non-aromatic heterocyclic groups containing up to 3 heteroatoms selected from N, O and S and being optionally substituted with one to three substituents selected from C_{1-4} alkyl, trifluoromethyl, fluoro and chloro;
- cyano, nitro, amino, C_{1-4} alkylamino, di-C_{1-4}alkylamino, C_{1-4} acylamino, C_{1-4} alkoxycarbonylamino;
- a group R^{19}-$S(O)_n$- where n is 0, 1 or 2 and R^{19} is selected from amino; C_{1-4} alkylamino; di-C_{1-4}alkylamino; C_{1-4} hydrocarbyl; phenyl optionally substituted with one to three substituents selected from C_{1-4} alkyl, trifluoromethyl, fluoro and chloro; and 5- and 6-membered non-aromatic heterocyclic groups containing up to 3 heteroatoms selected from N, O and S and being optionally substituted with one to three C_{1-4} alkyl group substituents; and
- a group R^{20}-Q- where R^{20} is phenyl optionally substituted with one to three substituents selected from C_{1-4} alkyl, trifluoromethyl, fluoro and chloro; and Q is a linker group selected from OCH_2, CH_2O, NH, CH_2NH, NCH_2, CH_2, NHCO and CONH.

113. (New) A compound according to claim 82, or a salt or N-oxide thereof, wherein A is NH(C=O) or (C=O), and R^{1d} is a group R^{1b}, wherein R^{1b} is a substituted phenyl group having from 1 to 4 substituents whereby:

(i) when R^{1b} bears a single substituent it is selected from halogen, hydroxyl, C_{1-4} hydrocarbyloxy optionally substituted by one or more substituents selected from hydroxyl and halogen; C_{1-4} hydrocarbyl substituted by one or more substituents selected from hydroxyl and halogen; heteroaryl group having 5 ring members; and 5- and 6-membered non-aromatic heterocyclic groups, wherein the heteroaryl and heterocyclic groups contain up to 3 heteroatoms selected from N, O and S; and

(ii) when R^{1b} bears 2, 3 or 4 substituents, each is selected from halogen, hydroxyl, C_{1-4} hydrocarbyloxy optionally substituted by one or more substituents selected from hydroxyl and halogen; C_{1-4} hydrocarbyl optionally substituted by one or more substituents selected from hydroxyl and halogen; heteroaryl groups having 5 ring members; amino; and 5- and 6-membered non-aromatic heterocyclic groups; or two adjacent substituents together with the carbon atoms to which they are attached form a 5-membered heteroaryl ring or a 5- or 6-membered non-aromatic heterocyclic ring; wherein the said heteroaryl and heterocyclic groups contain up to 3 heteroatoms selected from N, O and S.

114. (New) A compound according to claim 82, or a salt or N-oxide thereof, wherein R^{1d} is a group R^{1c}, wherein R^{1c} is selected from:

(a) a mono-substituted phenyl group wherein the substituent is selected from *o*-amino, *o*-methoxy; *o*-chloro; *p*-chloro; *o*-difluoromethoxy; *o*-trifluoromethoxy; *o*-*tert*-butyloxy; *m*-methylsulphonyl and *p*-fluoro;

(b) a 2,4- or 2,6-disubstituted phenyl group wherein one substituent is selected from *o*-methoxy, *o*-ethoxy, *o*-fluoro, and *p*-morpholino and the other substituent is selected from *o*-fluoro, *o*-chloro, *p*-chloro, and *p*-amino;

(c) a 2,5-disubstituted phenyl group wherein one substituent is selected from *o*-fluoro and *o*-methoxy and the other substituent is selected from *m*-methoxy, *m*-isopropyl; *m*-fluoro, *m*-trifluoromethoxy, *m*-trifluoromethyl, *m*-methylsulphanyl, *m*-pyrrolidinosulphonyl, *m*-(4-methylpiperazin-1-yl)sulphonyl, *m*-morpholinosulphonyl, *m*-methyl, *m*-chloro and *m*-aminosulphonyl;

(d) a 2,4,6-tri-substituted phenyl group where the substituents are the same or different and are each selected from *o*-methoxy, *o*-fluoro, *p*-fluoro, and *p*-methoxy provided that no more than one methoxy substituent is present;

(e) a 2,4,5-tri-substituted phenyl group where the substituents are the same or different and are each selected from *o*-methoxy, *m*-chloro and *p*-amino;

(f) unsubstituted benzyl; 2,6-difluorobenzyl; α,α-dimethylbenzyl; 1-phenylcycloprop-1-yl; and α-tert-butoxycarbonylaminobenzyl;

(g) an unsubstituted 2-furyl group or a 2-furyl group bearing a single substituent selected from 4-(morpholin-4-ylmethyl) and piperidinylmethyl; and optionally a further substituent selected from methyl;

(h) an unsubstituted pyrazolo[1,5-a]pyridin-3-yl group;

(i) isoxazolyl substituted by one or two C_{1-4} alkyl groups;

(j) 4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl;

(k) 3-tert-butyl-phenyl-1H-pyrazol-5-yl;

(l) quioxalinyl;

(m) benz[c]isoxazol-3-yl;

(n) 2-methyl-4-trifluoromethyl-thiazol-5-yl;

(o) 3-phenylamino-2-pyridyl;

(p) 1-toluenesulphonylpyrrol-3-yl;

(q) 2,4-dimethoxy-3-pyridyl; and 6-chloro-2-methoxy-4-methyl-3-pyridyl;

(r) imidazo[2,1-b]thiazol-6-yl;

(s) 5-chloro-2-methylsulphanyl-pyrimidin-4-yl;

(t) 3-methoxy-naphth-2-yl;

(u) 2,3-dihydro-benz[1,4]dioxin-5-yl;

(v) 2,3-dihydro-benzfuranyl group optionally substituted in the five membered ring by one or two methyl groups;

(w) 2-methyl-benzoxazol-7-yl;

(x) 4-aminocyclohex-1-yl;

(y) 1,2,3,4-tetrahydro-quinolin-6-yl;

(z) 2-methyl-4,5,6,7-tetrahydro-benzfuran-3-yl;

(aa) 2-pyrimidinyl-1-piperidin-4-yl; and 1-(5-trifluoromethyl-2-pyridyl)-piperidin-4-yl and 1-methylsulphonylpiperidin-4-yl;

(ab) 1-cyanocyclopropyl; and

(ac) N-benzylmorpholin-2-yl;

and when A is NH(C=O), R^{1c} is additionally selected from:

(ad) unsubstituted phenyl.

115. (New) A compound according to claim 83, or a salt or N-oxide thereof, wherein A is NH(C=O).

116. (New) A compound according to claim 83, or a salt or N-oxide thereof, wherein A is C=O.

117. (New) A compound according to claim 101, or a salt or N-oxide thereof, wherein R^1 is unsubstituted.

118. (New) A compound according to claim 101, or a salt or N-oxide thereof, wherein R^1 is substituted by 1 or 2 or 3 or 4 substituents R^{10}.

119. (New) A compound according to claim 82, wherein the compound is in the form of a salt.

120. (New/Withdrawn) A method for the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase or glycogen synthase kinase-3 or an Aurora kinase, which method comprises administering to a subject in need of such administration a prophylactically or therapeutically effective amount of a compound according to claim 82, or a salt or N-oxide thereof,.

121. (New/Withdrawn) A method according to claim 120 wherein the disease state or condition is mediated by a cyclin dependent kinase or glycogen synthase kinase.

122. (New/Withdrawn) A method according to claim 120 wherein the disease state or condition is mediated by an Aurora kinase.

123. (New/Withdrawn) A method according to claim 120 wherein the disease state or condition is a proliferative disorder.

124. (New/Withdrawn) A method according to claim 123 wherein the proliferative disorder is a cancer.

125. (New/Withdrawn) A method according to claim 124 wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer, and non-small cell lung carcinomas.

126. (New/Withdrawn) A method according to claim 120 wherein the disease state or condition is selected from the group consisting of cancers, viral infections, autoimmune disease, and neurodegenerative disorders.

127. (New/Withdrawn) A method according to claim 126 wherein the disease state or condition is a cancer.

128. (New/Withdrawn) A method according to claim 127 wherein the cancer is a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, or skin; a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.

129. (New/Withdrawn) A method according to claim 128 wherein the cancer is a hematopoietic tumour of lymphoid lineage selected from leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, and Burkett's lymphoma.

130. (New/Withdrawn) A method according to claim 129 wherein the cancer is a hematopoietic tumour of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome, and promyelocytic leukemia.

131. (New/Withdrawn) A method according to claim 127 wherein the disease state or condition is a cancer selected from breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer, and non-small cell lung carcinomas.

132. (New/Withdrawn) A method according to claim 127 wherein the cancer is selected from breast, bladder, colorectal, pancreatic, ovarian, non-Hodgkin's lymphoma, gliomas and nonendometrioid endometrial carcinomas.

133. (New/Withdrawn) A method for the prophylaxis or treatment of a disease state or condition characterized by up-regulation of an Aurora kinase, which method comprises administering to a subject a prophylactically or therapeutically effective amount of a compound according to claim 82.

134. (New/Withdrawn) A method for the prophylaxis or treatment of cancer in a patient suffering from or suspected of suffering from cancer; which method comprises (i) subjecting a patient to a diagnostic test to determine whether the patient possesses the Ile31 variant of the Aurora A gene; and (ii) where the patient does possess the said variant, thereafter administering to the patient a prophylactically or therapeutically effective amount of a compound according to claim 82.

135. (Withdrawn) A method for the prophylaxis or treatment of a disease state or condition characterised by up-regulation of an Aurora kinase; which method comprises (i) subjecting a patient to a diagnostic test to detect a marker characteristic of up-regulation of the Aurora kinase and (ii) where the diagnostic test is indicative of up-regulation of Aurora kinase, thereafter administering to the patient a prophylactically or therapeutically effective amount of a compound of the formula (I) as defined in claim 82.